MMP3 Gene Coronary Heart Disease Susceptibility to Type 6 Genetic Test
Components
- Test Name: MMP3 Gene Coronary Heart Disease Susceptibility to Type 6 Genetic Test
- Price: 4400.0 AED
- Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
- Report Delivery: 3 to 4 Weeks
- Method: NGS Technology
- Test Type: Cardiovascular Pneumology Disorders
- Doctor: Cardiologist
- Test Department: Genetics
Pre Test Information
Clinical History of Patient who is going for MMP3 Gene Coronary Heart Disease, Susceptibility to, Type 6 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with MMP3 Gene Coronary Heart Disease, Susceptibility to, Type 6 NGS Genetic DNA Test gene MMP3.
Test Details
MMP3 gene, also known as matrix metallopeptidase 3, is a gene that encodes an enzyme called stromelysin-1. This enzyme is involved in the breakdown of extracellular matrix components, such as collagen and proteoglycans.
Coronary heart disease (CHD) is a condition characterized by the narrowing of the coronary arteries that supply blood to the heart. It is a multifactorial disease, meaning that both genetic and environmental factors contribute to its development.
NGS (Next-Generation Sequencing) genetic testing is a method used to analyze an individual’s DNA for specific genetic variants or mutations. In the context of CHD, NGS genetic testing can be used to identify genetic variants in the MMP3 gene that may be associated with an increased susceptibility to the disease.
CHD susceptibility type 6 refers to a specific variant or mutation in the MMP3 gene that has been linked to an increased risk of developing coronary heart disease. By performing NGS genetic testing, individuals can determine if they carry this specific variant and assess their risk for developing CHD.
It is important to note that genetic testing for CHD susceptibility is just one piece of the puzzle and should be interpreted in conjunction with other risk factors, such as family history, lifestyle, and other genetic variants. Genetic testing alone cannot predict the development or progression of CHD with certainty, but it can provide valuable information for individuals and their healthcare providers to make informed decisions about prevention and treatment strategies.
| Test Name | MMP3 Gene Coronary heart disease susceptibility to type 6 Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Cardiovascular Pneumology Disorders |
| Doctor | Cardiologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for MMP3 Gene Coronary heart disease, susceptibility to, type 6 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with MMP3 Gene Coronary heart disease, susceptibility to, type 6 NGS Genetic DNA Test gene MMP3 |
| Test Details |
MMP3 gene, also known as matrix metallopeptidase 3, is a gene that encodes an enzyme called stromelysin-1. This enzyme is involved in the breakdown of extracellular matrix components, such as collagen and proteoglycans. Coronary heart disease (CHD) is a condition characterized by the narrowing of the coronary arteries that supply blood to the heart. It is a multifactorial disease, meaning that both genetic and environmental factors contribute to its development. NGS (Next-Generation Sequencing) genetic testing is a method used to analyze an individual’s DNA for specific genetic variants or mutations. In the context of CHD, NGS genetic testing can be used to identify genetic variants in the MMP3 gene that may be associated with an increased susceptibility to the disease. CHD susceptibility type 6 refers to a specific variant or mutation in the MMP3 gene that has been linked to an increased risk of developing coronary heart disease. By performing NGS genetic testing, individuals can determine if they carry this specific variant and assess their risk for developing CHD. It is important to note that genetic testing for CHD susceptibility is just one piece of the puzzle and should be interpreted in conjunction with other risk factors, such as family history, lifestyle, and other genetic variants. Genetic testing alone cannot predict the development or progression of CHD with certainty, but it can provide valuable information for individuals and their healthcare providers to make informed decisions about prevention and treatment strategies. |
